Form 4: Moderna Director Robert Langer Granted Stock Options

Director Robert Langer of Moderna, Inc. was granted stock options for 7,557 shares on May 6, 2024, exercisable by May 6, 2025, or the next Annual Meeting of Stockholders.

Summary

• On May 6, 2024, Robert Langer, a director of Moderna, Inc., was granted stock options to purchase 7,557 shares of Moderna's common stock.
• The exercise price of these options is $122.13 per share.
• The options will vest and become exercisable on the earlier of May 6, 2025, or Moderna's next Annual Meeting of Stockholders, contingent upon Langer's continued service.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction (stock option grant) and doesn't inherently convey strong positive or negative sentiment. It's a neutral event from an investment perspective.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
• Companies like Pfizer, BioNTech, and Johnson & Johnson also utilize stock options as part of their executive compensation plans.
• The vesting schedules and exercise prices are typically structured to align with company performance and long-term value creation.

Stakeholder Impact

• The granting of stock options can positively impact shareholders by aligning the interests of directors with the long-term performance of the company.
• Employees may view this as a positive sign of the company's commitment to its leadership.

Key Dates